Overview

Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone

Status:
Recruiting

Trial end date:
2023-04-05

Target enrollment:

Participant gender:

Summary

The main objective of this study is to evaluate the efficacy of SZC as compared with placebo in keeping potassium levels within the normal range (3.5-5.0 mEq/L) while on spironolactone ≥25 mg daily without assistance of rescue therapy for hyperkalaemia (HK).

Phase:

Phase 4

Details

Lead Sponsor:

AstraZeneca

Treatments:

Spironolactone